Stay informed with the latest litigation news. Explore now

IP Verse

Celgene competitive analysis

Latest publications and patents of Celgene New

Explore the latest publications and patents granted to Celgene, showcasing their recent innovations and technological advancements.

Last updated on: Sep 4, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Celgene

EP3925609
Jul 30, 2025Methods Of Treating Multiple Myeloma With Immunomodulatory Compounds In Combination With AntibodiesGranted
EP3399980
Jul 16, 2025Methods For Treating Cancer And The Use Of Biomarkers As A Predictor Of Clinical Sensitivity To TherapiesGranted
EP4582105
Jul 9, 2025Formulations Of 4-Amino-2-(2,6-Dioxopiperidine-3-Yl)Isoindoline-1,3-DionePending
EP4562013
Jun 4, 2025Substituted Imidazopyrazine Compounds As Irak3 BindersPending
EP4562012
Jun 4, 2025Substituted Imidazopyrazine Compounds As Ligand Directed Degraders Of Irak3Pending
EP4562008
Jun 4, 2025Substituted Pyrazolyl-Pyridinyl Compounds As Ligand Directed Degraders Of Irak3Pending
EP4359404
Jun 4, 2025Cereblon Binding Compounds, Compositions Thereof, And Methods Of Treatment TherewithPending
EP4558495
May 28, 2025Heteroaryl Compounds As Ligand Directed Degraders Of Irak4Pending
EP4558480
May 28, 2025Compounds For The Treatment Of Neurodegenerative DiseasesPending
EP4494711
May 21, 2025Substituted 3-((3-Aminophenyl)Amino)Piperidine-2,6-Dione Compounds, Compositions Thereof, And Methods Of Treatment TherewithPending

Latest patents of Celgene opposed by its competitors

Explore Celgene's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 11, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3638243
Aug 7, 2024Methods For Treating Myeloproliferative Neoplasm-Associated Myelofibrosis And Anemia2
EP2498610
Jun 19, 2024Selective Sphingosine 1 Phosphate Receptor Modulators And Methods Of Chiral Synthesis1
EP3782612
Nov 8, 2023Oral Formulations Of Cytidine Analogs And Methods Of Use Thereof5
EP3370729
Sep 27, 2023Methods For The Identification, Evaluation And Treatment Of Patients Having Multiple Myeloma1
EP2651400
Jan 18, 2023Controlled Release Oral Dosage Forms Of Poorly Soluble Drugs And Uses Thereof1
EP3880802
Sep 7, 2022Improved T Cell Manufacturing Process1
EP3782611
Jul 6, 2022Oral Formulations Of Cytidine Analogs And Methods Of Use Thereof5
EP3692983
Aug 11, 2021Oral Formulations Of Cytidine Analogs And Methods Of Use Thereof6
EP3320902
Feb 17, 2021Methods For Treating Diseases Using Isoindoline Compounds1
EP2797581
May 6, 2020Formulations Of (+)-2-[1-(3-Ethoxy-4-Methoxy-Phenyl)-2-Methanesulfonyl-Ethyl]-4-Acetyl Aminoisoindoline-1,3-Dione3

Latest PTAB cases involving Celgene New

Discover the latest PTAB cases involving Celgene, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 10, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Celgene

IPR2023-00512Feb 10, 2023APOTEXCELGENETerminated-Settled
IPR2018-01714Sep 12, 2018ALVOGEN PINE BROOKCELGENEInstitution Denied
IPR2018-01509Aug 3, 2018DR REDDYS LABORATORIESCELGENEInstitution Denied
IPR2018-01507Aug 3, 2018DR REDDYS LABORATORIESCELGENEInstitution Denied
IPR2018-01504Aug 3, 2018DR REDDYS LABORATORIESCELGENEInstitution Denied
IPR2018-00685Feb 23, 2018APOTEXCELGENEInstitution Denied
IPR2015-01169May 7, 2015COALITION FOR AFFORDABLE DRUGS VICELGENEInstitution Denied
IPR2015-01103Apr 23, 2015COALITION FOR AFFORDABLE DRUGS VICELGENEFinal Written Decision
IPR2015-01102Apr 23, 2015COALITION FOR AFFORDABLE DRUGS VICELGENEFinal Written Decision
IPR2015-01096Apr 23, 2015COALITION FOR AFFORDABLE DRUGS VICELGENEFinal Written Decision

Top competitors of Celgene

Top competitors of Celgene based on patent oppositions.